Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorMallo, Maria del Mar
dc.contributor.authorTuechler, Heinz
dc.contributor.authorArenillas, Leonor
dc.contributor.authorRaynaud, Sophie
dc.contributor.authorCluzeau, Thomas
dc.contributor.authorShih, Lee-Yung
dc.contributor.authorPalomo Diaz, Laura
dc.date.accessioned2023-05-25T07:38:06Z
dc.date.available2023-05-25T07:38:06Z
dc.date.issued2023-05
dc.identifier.citationMallo M, Tuechler H, Arenillas L, Raynaud S, Cluzeau T, Shih LY, et al. Regions of homozygosity confer a worse prognostic impact in myelodysplastic syndrome with normal karyotype. EJHaem. 2023 May;4(2):446–9.
dc.identifier.issn2688-6146
dc.identifier.urihttps://hdl.handle.net/11351/9617
dc.descriptionChromosome; Cytogenetics; Myelodysplastic syndromes
dc.description.abstractHalf of the myelodysplastic syndromes (MDS) have normal karyotype by conventional banding analysis. The percentage of true normal karyotype cases can be reduced by 20–30% with the complementary application of genomic microarrays. We here present a multicenter collaborative study of 163 MDS cases with a normal karyotype (≥10 metaphases) at diagnosis. All cases were analyzed with the ThermoFisher® microarray (either SNP 6.0 or CytoScan HD) for the identification of both copy number alteration(CNA) and regions of homozygosity (ROH). Our series supports that 25 Mb cut-off as having the most prognostic impact, even after adjustment by IPSS-R. This study highlights the importance of microarrays in MDS patients, to detect CNAs and especially to detect acquired ROH which has demonstrated a high prognostic impact.
dc.language.isoeng
dc.publisherWiley
dc.relation.ispartofseriesEJHaem;4(2)
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectSíndromes mielodisplàsiques - Aspectes genètics
dc.subjectSíndromes mielodisplàsiques - Prognosi
dc.subject.meshMyelodysplastic Syndromes
dc.subject.meshPrognosis
dc.titleRegions of homozygosity confer a worse prognostic impact in myelodysplastic syndrome with normal karyotype
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1002/jha2.651
dc.subject.decssíndromes mielodisplásicos
dc.subject.decspronóstico
dc.relation.publishversionhttps://doi.org/10.1002/jha2.651
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Mallo M] MDS Research Group, Institut de Recerca Contra la Leucèmia Josep Carreras (IJC), ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain. Microarrays Unit, Institut de Recerca Contra la Leucèmia Josep Carreras (IJC), ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain. [Tuechler H] Boltzmann Institute for Leukaemia Research and Hematology, Vienna, Austria. [Arenillas L] Hematological Cytology Laboratory, Pathology Department, Hospital del Mar, GRETNHE, IMIM (Hospital del Mar Research Institute), Barcelona, Spain. [Raynaud S, Cluzeau T] Hematology Department, Cote d’Azur University, CHU of Nice, Nice, France. [Shih LY] Division of Hematology, Chang Gung Memorial Hospital-Linkuo, Chang Gung University, Taoyuan City, Taiwan. [Palomo L] Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
dc.identifier.pmid37206269
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record